Ensysce Biosciences Inc Revenue Growth Rates (ENSC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ensysce Biosciences Inc   (NASDAQ: ENSC)
 

ENSC's Revenue Growth by Quarter and Year

Ensysce Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENSC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.96
FY 0.96

ENSCs Annual Revenue
Ensysce Biosciences Inc 's Revenue in the fiscal year 2025 $ 5.07 millions
Ensysce Biosciences Inc 's Revenue in the fiscal year 2024 $ 5.21 millions
Ensysce Biosciences Inc 's Revenue in the fiscal year 2023 $ 2.23 millions
Ensysce Biosciences Inc 's Revenue in the fiscal year 2022 $ 2.52 millions
Ensysce Biosciences Inc 's Revenue in the fiscal year 2021 $ 3.53 millions




ENSC Revenue first quarter 2026 Y/Y Growth Comment
Ensysce Biosciences Inc reported fall in Revenue in the first quarter 2026 by -27.2% to $ 0.96 millions, from the same quarter in 2025.
The drop in the first quarter 2026 Ensysce Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 147.31%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue growth. While Ensysce Biosciences Inc ' s Revenue drop of -27.2% ranks overall at the positon no. 729 in the first quarter 2026.


ENSC Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 44.62 % 150 % 85.71 %
3rd Quarter September - -85.67 % 597.96 % 133.33 %
2nd Quarter June - 661.11 % -77.22 % 31.67 %
1st Quarter March -27.2 % 325.81 % -78.32 % -12.8 %
FY   - -2.88 % 61.3 % -

Financial Statements
Ensysce Biosciences Inc 's first quarter 2026 Revenue $ 0.96 millions ENSC's Income Statement
Ensysce Biosciences Inc 's first quarter 2025 Revenue $ 1.32 millions Quarterly ENSC's Income Statement


ENSC Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 283.67 % -61.99 % 6.12 %
3rd Quarter September - -64.23 % 1800 % -37.97 %
2nd Quarter June - 3.79 % -41.94 % -44.76 %
1st Quarter March -48.88 % 1.54 % -40.38 % 410.71 %
FY (Year on Year)   - -2.88 % 61.3 % -


Back to ENSC Growth rate Comparisons >> Back to ENSC Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #154
Overall #729

Revenue Y/Y Growth Statistics
High Average Low
717.62 % 147.31 % -39.15 %
(Jun 30 2023)   (Jun 30 2024)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #154
Overall #729
Revenue Y/Y Growth Statistics
High Average Low
717.62 % 147.31 % -39.15 %
(Jun 30 2023)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ensysce Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1780.59 % 151.14 % -65.6 %
(Sep 30 2024)  


ENSC's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Ensysce Biosciences Inc disclosed fall in Revenue from the fourth quarter by -48.88% to $ 0.96 millions, from $ 1.88 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Ensysce Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 3284.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #462
Overall #3284
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #462
Overall #3284
Revenue Q/Q Growth Statistics
High Average Low
1780.59 % 151.14 % -65.6 %
(Sep 30 2024)  


ENSC's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Ensysce Biosciences Inc disclosed fall in Revenue from the fourth quarter by -48.88% to $ 0.96 millions, from $ 1.88 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Ensysce Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 3284.


Ensysce Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 4.71 $ 5.07 $ 4.49 $ 7.41 $ 6.22
Y / Y Revenue Growth (TTM) -24.36 % -2.75 % 1.51 % 396.56 % 196.26 %
Year on Year Revenue Growth Overall Ranking # 78 # 217 # 164 # 2757 # 2824
Seqeuential Revenue Change (TTM) -7.08 % 12.89 % -39.46 % 19.11 % 19.46 %
Seq. Revenue Growth (TTM) Overall Ranking # 729 # 902 # 69 # 2685 # 3236


Cumulative Revenue growth Comment
Ensysce Biosciences Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -24.36% year on year, at Mar 31 2026 compare to the -2.75% decrease at Dec 31 2025. If the Ensysce Biosciences Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $5 millions.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 78, from total ranking in previous quarter at 217.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 28
Overall # 78

Revenue TTM Y/Y Growth Statistics
High Average Low
717.62 %
 147.31 %
-39.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 61
Sector # 154
S&P 500 # 729
Cumulative Revenue growth Comment
Ensysce Biosciences Inc 's cumulative 12 months Revenue continue to fall, but on the faster rate at -24.36% year on year, at Mar 31 2026 compare to the -2.75% decrease at Dec 31 2025. If the Ensysce Biosciences Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $5 millions.

Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 78, from total ranking in previous quarter at 217.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 28
Overall # 78

Revenue TTM Y/Y Growth Statistics
High Average Low
717.62 %
147.31 %
-39.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 61
Sector # 154
S&P 500 # 729




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENSC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Ensysce Biosciences Inc Revenue Growth Rates (ENSC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ensysce Biosciences Inc (CIK 1716947).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-037817
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ensysce Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.